Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-two patients with refractory non-Hodgkin's lymphoma were treated with high-dose cytosine arabinoside (ara-C) given at 2 g/m2 IV over three hours every 12 hours for 4-8 g/m2/course repeated at three to four week intervals. There were eight partial responses (29%) and two minor responses among 28 evaluable patients. The median response duration was 10 weeks (range, 6-33 weeks). The median survival was significantly prolonged in responders compared to nonresponders (28 versus 15 weeks; p = 0.03). Two additional patients treated with 12 g/m2/course died of sepsis and myelosuppression. The dose-limiting toxicity was myelosuppression, which was more pronounced in patients with prior extensive radiation therapy and bone marrow involvement. In vivo measurements of intracellular concentrations of ara-CTP, the active metabolite of ara-C, showed significantly higher values in bone marrows with lymphomatous involvement compared to normal bone marrows (210 versus 95 microM; p = 0.05), probably indicating a preferential formation and retention of ara-CTP in malignant cells compared to normal hemopoietic cells. In addition, higher ara-CTP levels were found in bone marrows that had higher percentages of cells in S phase.
 ...
PMID:High-dose cytosine arabinoside in non-Hodgkin's lymphoma. 636 30

A total of 164 patients with non-Hodgkin's lymphoma (NHL) were randomized to receive cycles of treatment every 3 weeks with either CTP, ie, cyclophosphamide (400 mg/m2/day orally X 5), teniposide (VM-26) (100 mg/m2 iv X 1), and prednisolone (60 mg/m2/day orally X 5), or COP, ie, vincristine (1.4 mg/m2 iv X 1; maximum, 2 mg) with the same cyclophosphamide and prednisolone doses listed above. Results were analyzed according to whether the patients' NHL histology was favorable (47 patients) or unfavorable (117). The great majority of patients in each group had advanced disease (stage IV in 70% and stage III in 20%). For each histologic group, the results with the two regimens were similar with respect to remission incidence and survival. In favorable-histology NHL, CTP produced 57% complete remissions (CR) and 29% partial remissions (PR), compared with 54% CR and 19% PR for COP. Survival in these patients was also similar for the two regimens, the relative death rates being 1.13 for CTP-treated patients and 0.88 for COP-treated patients (P = 0.75). In patients with unfavorable-histology NHL, CTP produced 38% CR and 28% PR, compared with 43% CR and 35% PR for COP, the relative death rates being 1.10 for CTP-treated patients and 0.90 for COP-treated patients (P = 0.49). Neurotoxicity was virtually absent in patients treated with CTP, whereas in COP-treated patients it was severe in 12% and moderate in 36%. Other toxic effects occurred with equivalent frequency in the two regimens. These results show that teniposide can replace vincristine in combination with cyclophosphamide and prednisolone in the treatment of NHL, with freedom from neurotoxicity and comparable survival and response rates.
 ...
PMID:Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma. 705 65